Skip to main content
Clinical Trials/NCT02238418
NCT02238418
Completed
Phase 4

Vitamin D Supplementation in Children and Adolescents Seen in the Paediatric Nephrology Service: Study of the Efficacy of Service Usual Care (Cholecalciferol) and Its Impact on Calciuria.

Hospices Civils de Lyon1 site in 1 country43 target enrollmentSeptember 1, 2014

Overview

Phase
Phase 4
Intervention
Cholecalciferol vial (100 000 UI)
Conditions
Chronic Kidney Disease
Sponsor
Hospices Civils de Lyon
Enrollment
43
Locations
1
Primary Endpoint
Efficacy of usual vitamin D supplementation
Status
Completed
Last Updated
8 months ago

Overview

Brief Summary

Vitamin D is not seen anymore only as a phosphocalcic and bone hormone, but also as having an effect on global health (anti-infective, anti-inflammatory, anti-tumour roles and cardiovascular protection).

Until recently, vitamin D repletion was defined as the minimal concentration that enables the prevention of rickets in children and osteomalacia in adults, i.e, approximately 8 ng/mL (20 nmol/L). However, most of the international experts agree to set minimal threshold of 25 OH vitamin D serum concentration, higher than the one previously admitted, with a limit of 20 ng/mL (50 nmol/L) to define a vitamin D deficiency and a limit of 30 ng/mL (75 nmol/L) to define vitamin D insufficiency.

Recommendations for Vit D supplementation in healthy children were updated in France in 2012. The invariable supplementation of infants and toddlers is efficient since deficiency-related rickets have almost disappeared; however there is very few information in ill children populations.

Vit D supplementation tolerance is usually considered as good and over-dosage risks are low, however these studies were conducted more than 30 years ago, and as far as we know, there is no study about calcium urinary excretion kinetics after intake of a 100 000 IU vial of cholecalciferol (Uvedose®). When 25 OH vitamin D serum concentrations exceeds 200 ng/mL, which is very rare in daily practice, toxic effects of Vit D may theoretically be observed, particularly hypercalcemia and hypercalciuria.

Vitamin D deficit is very common in children with chronic kidney disease (CKD) with a 50 to 92% prevalence depending on the studies; it it is a risk factor for secondary hyperparathyroidism.

Although international guidelines regarding the care of CKD children recommend 25 OH vitamin D serum concentrations over 75 nmol/L, there are no practical recommendations in terms of dose and frequency of native Vit D treatment.

Therefore, the objectives of the present study has are the following:

  • to validate prospectively the efficacy of our service usual care for Vit D supplementation of children and adolescents seen in the paediatric nephrology department.
  • and to study the effect of Vit D supplementation (100 000 IU vial of cholecalciferol) on calciuria in these patients.
Registry
clinicaltrials.gov
Start Date
September 1, 2014
End Date
October 1, 2017
Last Updated
8 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age : between \[18 mo et 18 yo\[
  • Patients seen in the paediatric nephrology service and having :
  • Chronic kidney disease
  • Renal transplant
  • Stable nephrotic syndrome (i.e., normal protidemia at inclusion)
  • Initial 25 OH vitamin D concentration \< 75nmol/l
  • Patient agree to participate (if old enough to give his agreement) and written informed consent signed by parents
  • Patients affiliated within the French universal healthcare system

Exclusion Criteria

  • \- Contraindication to 100 000 IU Uvedose® treatment (according to the Summary of Product Characteristics: known hypersensitivity to vitamin D or hypercalcemia, hypercalciuria or nephrolithiasis).

Arms & Interventions

Usual vitamin D supplementation

Intervention: Cholecalciferol vial (100 000 UI)

Outcomes

Primary Outcomes

Efficacy of usual vitamin D supplementation

Time Frame: Day 60

The 25 OH vitamin D serum concentration will be measured at inclusion (before treatment intake) and 2 months after supplementation. No extra blood intake is programmed since this parameter is always measured in this population. The main evaluation criterion is defined as a 25 OH vitamin D serum concentration over 75 nmol/l at month 2. This defines the success of supplementation. The failure is defined as a 25 OH vitamin D serum concentration under 75 nmol/l at month 2.

Secondary Outcomes

  • Kinetics of calciuria after a 100 000 IU vial of cholecalciferol(Day 0, day 1, day 2, day 3, day 4, day 7 after treatment intake.)

Study Sites (1)

Loading locations...

Similar Trials